What is Solesence's earnings per share (EPS)?

Solesence (SLSN) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a -71.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Solesence Financials

SLSN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Solesence (SLSN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 45/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Solesence has an operating margin of 2.5%, meaning the company retains $3 of operating profit per $100 of revenue. This below-average margin results in a low score of 28/100, suggesting thin profitability after operating expenses. This is down from 9.8% the prior year.

Growth

Solesence's revenue surged 18.0% year-over-year to $61.8M, reflecting rapid business expansion. This strong growth earns a score of 63/100.

Leverage

Solesence carries a low D/E ratio of 1.84, meaning only $1.84 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Solesence's current ratio of 2.07 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Solesence's ROE of 10.2% shows moderate profitability relative to equity, earning a score of 34/100. This is down from 28.3% the prior year.

Altman Z-Score Distress

0.76

Solesence scores 0.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($98.9M) relative to total liabilities ($32.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Weak

3/9

Solesence passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

-4.79x

For every $1 of reported earnings, Solesence generates $-4.79 in operating cash flow (-$8.6M OCF vs $1.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

1.4x

Solesence earns $1.4 in operating income for every $1 of interest expense ($1.6M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$61.8M

YoY+18.0%

5Y CAGR+29.3%

10Y CAGR+19.6%

Solesence generated $61.8M in revenue in fiscal year 2025. This represents an increase of 18.0% from the prior year.

EBITDA

$2.5M

YoY-59.3%

5Y CAGR+6.0%

Solesence's EBITDA was $2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 59.3% from the prior year.

Net Income

$1.8M

YoY-57.7%

5Y CAGR+12.6%

Solesence reported $1.8M in net income in fiscal year 2025. This represents a decrease of 57.7% from the prior year.

EPS (Diluted)

$0.02

YoY-71.4%

5Y CAGR-7.8%

Solesence earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 71.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.3M

YoY-8.6%

5Y CAGR+6.1%

10Y CAGR+0.1%

Solesence held $1.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

71M

YoY+0.8%

5Y CAGR+13.1%

10Y CAGR+9.5%

Solesence had 71M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

26.0%

YoY-4.9pp

5Y CAGR-9.0pp

10Y CAGR-4.2pp

Solesence's gross margin was 26.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.9 percentage points from the prior year.

Operating Margin

2.5%

YoY-7.3pp

5Y CAGR-6.1pp

10Y CAGR+14.0pp

Solesence's operating margin was 2.5% in fiscal year 2025, reflecting core business profitability. This is down 7.3 percentage points from the prior year.

Net Margin

2.9%

YoY-5.2pp

5Y CAGR-2.9pp

10Y CAGR+14.5pp

Solesence's net profit margin was 2.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 5.2 percentage points from the prior year.

Return on Equity

10.2%

YoY-18.2pp

5Y CAGR-26.0pp

10Y CAGR+51.8pp

Solesence's ROE was 10.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.1M

YoY+6.6%

5Y CAGR+21.1%

10Y CAGR+12.4%

Solesence invested $4.1M in research and development in fiscal year 2025. This represents an increase of 6.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SLSN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$61.8M+18.0%	$52.3M+40.4%	$37.3M-0.1%	$37.3M+26.6%	$29.5M+72.1%	$17.1M
Cost of Revenue	$46.0M+27.2%	$36.2M+22.7%	$29.5M+1.8%	$29.0M+39.3%	$20.8M+86.7%	$11.1M
Gross Profit	$16.1M-0.8%	$16.2M+106.9%	$7.8M-6.4%	$8.4M-3.8%	$8.7M+45.1%	$6.0M
R&D Expenses	$4.1M+6.6%	$3.8M0.0%	$3.8M+26.3%	$3.0M+35.9%	$2.2M+42.3%	$1.6M
SG&A Expenses	$10.4M+44.1%	$7.2M-4.2%	$7.5M-0.6%	$7.6M+94.6%	$3.9M+32.8%	$2.9M
Operating Income	$1.6M-69.4%	$5.1M+244.7%	-$3.5M-57.0%	-$2.3M-188.2%	$2.6M+72.3%	$1.5M
Interest Expense	$1.1M+67.6%	$670K-20.0%	$838K+119.4%	$382K-66.9%	$1.2M+132.7%	$496K
Income Tax	$73K-67.8%	$227K+3683.3%	$6K+135.3%	-$17K-145.9%	$37K	N/A
Net Income	$1.8M-57.7%	$4.2M+196.5%	-$4.4M-67.4%	-$2.6M-213.1%	$2.3M+134.6%	$989K
EPS (Diluted)	$0.02-71.4%	$0.07+177.8%	$-0.09-80.0%	$-0.05-200.0%	$0.05+66.7%	$0.03

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$14.6M-28.3%	$20.4M+39.2%	$14.6M+16.4%	$12.6M-25.5%	$16.9M+29.3%	$13.0M+32.2%	$9.9M+23.2%	$8.0M
Cost of Revenue	$11.2M-22.5%	$14.5M+28.8%	$11.2M+14.7%	$9.8M-8.9%	$10.8M+15.7%	$9.3M+48.0%	$6.3M-16.6%	$7.5M
Gross Profit	$3.4M-42.7%	$5.9M+73.8%	$3.4M+22.3%	$2.8M-54.7%	$6.1M+63.2%	$3.7M+4.5%	$3.6M+660.1%	$471K
R&D Expenses	$1.1M+13.3%	$955K-6.2%	$1.0M-6.9%	$1.1M+12.7%	$970K+12.3%	$864K-5.1%	$910K+15.8%	$786K
SG&A Expenses	$3.1M+1.9%	$3.0M+42.9%	$2.1M+11.1%	$1.9M-1.9%	$1.9M+5.7%	$1.8M+17.3%	$1.6M-1.6%	$1.6M
Operating Income	-$781K-140.9%	$1.9M+646.1%	$256K+214.3%	-$224K-107.0%	$3.2M+205.4%	$1.0M-5.8%	$1.1M+158.5%	-$1.9M
Interest Expense	N/A	N/A	$176K+63.0%	$108K-29.4%	$153K-19.9%	$191K-12.4%	$218K-2.2%	$223K
Income Tax	N/A	$390K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.1M-142.0%	$2.7M+3233.8%	$80K+114.3%	-$559K-118.4%	$3.0M+255.7%	$856K-4.1%	$893K+142.0%	-$2.1M
EPS (Diluted)	$-0.02-150.0%	$0.04	$0.00	N/A	$0.04+300.0%	$0.01-50.0%	$0.02	N/A

SLSN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$50.1M+0.1%	$50.0M+52.1%	$32.9M-2.0%	$33.6M+18.2%	$28.4M+109.7%	$13.5M
Current Assets	$28.8M-1.9%	$29.3M+80.0%	$16.3M-1.9%	$16.6M+43.3%	$11.6M+31.3%	$8.8M
Cash & Equivalents	$1.3M-8.6%	$1.4M-18.2%	$1.7M-21.2%	$2.2M+232.7%	$657K-31.3%	$957K
Inventory	$18.5M-8.7%	$20.3M+102.0%	$10.0M+13.5%	$8.8M+45.0%	$6.1M+40.4%	$4.3M
Accounts Receivable	$6.8M+40.4%	$4.9M+40.4%	$3.5M-26.8%	$4.7M+20.2%	$3.9M+34.3%	$2.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$32.4M-7.5%	$35.1M+13.2%	$31.0M+11.0%	$27.9M+33.4%	$20.9M+93.6%	$10.8M
Current Liabilities	$13.9M-46.0%	$25.8M+65.3%	$15.6M+12.7%	$13.8M+88.5%	$7.3M+8.2%	$6.8M
Long-Term Debt	N/A	N/A	N/A	$1.0M0.0%	$1.0M+5.0%	$952K
Total Equity	$17.6M+18.0%	$14.9M+685.8%	$1.9M-66.3%	$5.6M-24.3%	$7.5M+173.2%	$2.7M
Retained Earnings	-$98.6M+1.8%	-$100.4M+4.0%	-$104.7M-4.6%	-$100.1M-2.7%	-$97.4M+2.3%	-$99.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$54.0M-10.0%	$60.0M+5.2%	$57.0M+14.0%	$50.0M+4.1%	$48.0M+17.6%	$40.8M+6.1%	$38.5M+17.1%	$32.9M
Current Assets	$32.8M-15.4%	$38.8M+8.0%	$35.9M+22.3%	$29.3M-1.4%	$29.8M+22.7%	$24.3M+9.9%	$22.1M+35.4%	$16.3M
Cash & Equivalents	$429K-89.6%	$4.1M+126.1%	$1.8M+29.0%	$1.4M-51.8%	$2.9M+24.0%	$2.4M+16.8%	$2.0M+17.2%	$1.7M
Inventory	$18.9M-4.9%	$19.8M-9.5%	$21.9M+8.1%	$20.3M+34.7%	$15.0M+8.4%	$13.9M+4.5%	$13.3M+32.4%	$10.0M
Accounts Receivable	$9.7M-12.1%	$11.0M+21.6%	$9.1M+86.6%	$4.9M-44.2%	$8.7M+47.2%	$5.9M+13.5%	$5.2M+50.8%	$3.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$36.8M-12.0%	$41.8M-0.2%	$41.9M+19.4%	$35.1M+6.6%	$32.9M+13.7%	$28.9M-13.8%	$33.6M+8.3%	$31.0M
Current Liabilities	$17.9M-20.7%	$22.5M-31.5%	$32.9M+27.6%	$25.8M+10.7%	$23.3M+69.1%	$13.8M+13.1%	$12.2M-21.9%	$15.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$17.2M-5.3%	$18.2M+20.0%	$15.2M+1.4%	$14.9M-1.5%	$15.2M+27.2%	$11.9M+140.8%	$5.0M+160.3%	$1.9M
Retained Earnings	-$98.8M-1.1%	-$97.7M+2.7%	-$100.3M+0.1%	-$100.4M-0.6%	-$99.9M+3.0%	-$102.9M+0.8%	-$103.8M+0.9%	-$104.7M

SLSN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.6M-534.7%	$2.0M+198.3%	-$2.0M-21.6%	-$1.6M-171.1%	$2.3M+212.6%	-$2.1M
Capital Expenditures	N/A	$4.6M+333.7%	$1.1M-62.8%	$2.8M+50.6%	$1.9M+113.4%	$878K
Free Cash Flow	N/A	-$2.6M+15.4%	-$3.1M+31.7%	-$4.5M-1100.7%	$447K+115.2%	-$2.9M
Investing Cash Flow	-$2.1M+53.0%	-$4.6M-333.7%	-$1.1M+62.8%	-$2.8M-50.6%	-$1.9M-113.4%	-$878K
Financing Cash Flow	$10.6M+365.7%	$2.3M-12.3%	$2.6M-56.8%	$6.0M+903.5%	-$747K-127.6%	$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.5M-283.9%	-$654K+90.9%	-$7.2M-429.9%	$2.2M-47.9%	$4.2M+843.7%	-$565K+85.3%	-$3.9M-45.5%	-$2.6M
Capital Expenditures	N/A	N/A	N/A	$2.6M+84.8%	$1.4M+194.1%	$477K+461.2%	$85K-57.3%	$199K
Free Cash Flow	N/A	N/A	N/A	-$404K-114.4%	$2.8M+368.6%	-$1.0M+73.6%	-$3.9M-38.3%	-$2.8M
Investing Cash Flow	-$418K+70.3%	-$1.4M-1158.6%	$133K+105.1%	-$2.6M-84.8%	-$1.4M-194.1%	-$477K-461.2%	-$85K+57.3%	-$199K
Financing Cash Flow	-$750K-117.2%	$4.4M-41.9%	$7.5M+774.1%	-$1.1M+50.2%	-$2.2M-261.5%	$1.4M-67.4%	$4.2M+25.2%	$3.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLSN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	26.0%-4.9pp	30.9%+9.9pp	21.0%-1.4pp	22.4%-7.1pp	29.5%-5.5pp	35.0%
Operating Margin	2.5%-7.3pp	9.8%+19.3pp	-9.5%-3.5pp	-6.0%-14.7pp	8.7%+0.0pp	8.7%
Net Margin	2.9%-5.2pp	8.1%+19.9pp	-11.8%-4.7pp	-7.0%-14.9pp	7.9%+2.1pp	5.8%
Return on Equity	10.2%-18.2pp	28.3%+259.1pp	-230.8%-184.4pp	-46.4%-77.5pp	31.1%-5.1pp	36.2%
Return on Assets	3.6%-4.9pp	8.5%+21.8pp	-13.4%-5.5pp	-7.8%-16.0pp	8.2%+0.9pp	7.3%
Current Ratio	2.07+0.9	1.14+0.1	1.05-0.2	1.20-0.4	1.58+0.3	1.30
Debt-to-Equity	1.84-0.5	2.35-13.9	16.29+16.1	0.18+0.0	0.13-0.2	0.35
FCF Margin	N/A	-4.9%+3.3pp	-8.2%+3.8pp	-12.0%-13.5pp	1.5%+18.7pp	-17.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	23.1%-5.8pp	28.9%+5.8pp	23.1%+1.1pp	22.0%-14.2pp	36.2%+7.5pp	28.7%-7.6pp	36.3%+30.4pp	5.9%
Operating Margin	-5.3%-14.7pp	9.4%+7.6pp	1.8%+3.5pp	-1.8%-20.7pp	19.0%+10.9pp	8.0%-3.2pp	11.3%+35.0pp	-23.7%
Net Margin	-7.7%-20.8pp	13.1%+12.6pp	0.5%+5.0pp	-4.5%-22.5pp	18.1%+11.5pp	6.6%-2.5pp	9.0%+35.6pp	-26.6%
Return on Equity	-6.5%-21.2pp	14.7%+14.1pp	0.5%+4.3pp	-3.7%-23.8pp	20.1%+12.9pp	7.2%-10.9pp	18.0%+129.9pp	-111.9%
Return on Assets	-2.1%-6.5pp	4.5%+4.3pp	0.1%+1.3pp	-1.1%-7.5pp	6.3%+4.2pp	2.1%-0.2pp	2.3%+8.8pp	-6.5%
Current Ratio	1.84+0.1	1.72+0.6	1.09-0.0	1.14-0.1	1.28-0.5	1.76-0.1	1.81+0.8	1.05
Debt-to-Equity	2.13-0.2	2.30-0.5	2.76+0.4	2.35+0.2	2.17-0.3	2.43-4.4	6.78-9.5	16.29
FCF Margin	N/A	N/A	N/A	-3.2%-19.8pp	16.6%+24.6pp	-8.0%+31.9pp	-39.9%-4.4pp	-35.6%

Similar Companies

Waldencast plc WALD

$115.3M

European Wax Center, Inc. EWCZ

$255.7M

Acme United Corp ACU

$170.6M

Big Tree Cloud Holdings Limited DSY

$11.6M

The Beauty Health Company SKIN

$115.7M

Frequently Asked Questions

What is Solesence's annual revenue?

Solesence (SLSN) reported $61.8M in total revenue for fiscal year 2025. This represents a 18.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Solesence's revenue growing?

Solesence (SLSN) revenue grew by 18% year-over-year, from $52.3M to $61.8M in fiscal year 2025.

Is Solesence profitable?

Yes, Solesence (SLSN) reported a net income of $1.8M in fiscal year 2025, with a net profit margin of 2.9%.

What is Solesence's EBITDA?

Solesence (SLSN) had EBITDA of $2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Solesence's gross margin?

Solesence (SLSN) had a gross margin of 26.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Solesence's operating margin?

Solesence (SLSN) had an operating margin of 2.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Solesence's net profit margin?

Solesence (SLSN) had a net profit margin of 2.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Solesence's return on equity (ROE)?

Solesence (SLSN) has a return on equity of 10.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Solesence's operating cash flow?

Solesence (SLSN) generated -$8.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Solesence's total assets?

Solesence (SLSN) had $50.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Solesence spend on research and development?

Solesence (SLSN) invested $4.1M in research and development during fiscal year 2025.

How many shares does Solesence have outstanding?

Solesence (SLSN) had 71M shares outstanding as of fiscal year 2025.

What is Solesence's current ratio?

Solesence (SLSN) had a current ratio of 2.07 as of fiscal year 2025, which is generally considered healthy.

What is Solesence's debt-to-equity ratio?

Solesence (SLSN) had a debt-to-equity ratio of 1.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Solesence's return on assets (ROA)?

Solesence (SLSN) had a return on assets of 3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Solesence's cash runway?

Based on fiscal year 2025 data, Solesence (SLSN) had $1.3M in cash against an annual operating cash burn of $8.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Solesence's Altman Z-Score?

Solesence (SLSN) has an Altman Z-Score of 0.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Solesence's Piotroski F-Score?

Solesence (SLSN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Solesence's earnings high quality?

Solesence (SLSN) has an earnings quality ratio of -4.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Solesence cover its interest payments?

Solesence (SLSN) has an interest coverage ratio of 1.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Solesence?

Solesence (SLSN) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.